Biotech Values

[corpstrat]

>ZGEN – Do you have some reason other than yesterday's IMS announcement of the Feb sales?<

The short answer would have been, No.

As Clark and others have pointed out, we don't know how accurate, complete or meaningful Oppenheomer's Feb sales numbers are. We do know that Oppenheimer has been bashing ZGEN and hyping Omrix for months, so not exactly an unbiased source. Might as well wait and see what Zymo's actual numbers are when they report.

In any case Recothrom is at best a low-rev product and the real potential value in Zymo is from the other programs. At most Recothrom could be expected to contribute only a small amount of cash this year to defray Zymo's R&D. If it were not for the idiot analysts who value Zymo on Recothrom expected numbers only, the whole story would be much ado about close to nothing.